Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous AMB-05X in Tenosynovial Giant Cell Tumor
NCT04938180Phase 2Terminated
- Sponsor
- AmMax Bio
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ABM-05X in tenosynovial giant cell tumor (TGCT), sponsored by AmMax Bio. Primary endpoint: Treatment-emergent Adverse Events at 6 months. Started Sep 2021; status: terminated.
02
Drugs
ABM-05X
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT04938180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938180.